Pandemic: Covid-19 Goldman Sachs

Moderna, Goldman Sachs

Moderna slips as Goldman Sachs downgrades on revenue outlook

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue outlook. Read more here.

MarketWatch on MSN · 1d

Moderna’s stock is falling. Goldman Sachs says it’s no longer a buy.

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months.

Business Insider · 2d

Moderna downgraded to Neutral from Buy at Goldman Sachs

Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance

Goldman Sachs Predicts Gradual Recovery For Tools And Contract Research Sector In 2025, Stable Large Pharma Spending Key To Recovery

Goldman Sachs expects a gradual recovery in end-market growth throughout the year as the Tools and the contract research ...

Time27d

Why Congress Should Act Now To Prevent Another Pandemic

Formerly, he was the Undersecretary of State for Economic Development, Energy, and the Environment and Vice Chairman of Goldman ... pandemic. Five years ago, we underestimated the dangers of ...

13d

Goldman Sachs Expects $1 Trillion Of Stock Buybacks In 2025

U.S. investment bank Goldman Sachs (GS) is forecasting $1 trillion U.S. of stock buybacks in 2025, the most in the past five ...

20hon MSN

U.S. Economy Grew Slower Than Expected Last Quarter—Weakest Q4 Since 2018

After entering a technical recession in 2022, the U.S. economy has proven resilient even amid high interest rates.

Yen on MSN11d

In US, teleworkers don’t want to turn back after pandemic

Five years after the Covid-19 pandemic sent workers scrambling for home ... with few exceptions such as Goldman Sachs ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results